Stockreport

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population [Yahoo! Finance]

Cel-Sci Corporation  (CVM) 
NASDAQ:AMEX Investor Relations: cel-sci.com/investor_relations.html
PDF 73% survival for Multikine vs 45% in the control arm at 5 years Statistically significant log rank p = 0.0015 5-year risk of death cut in half from 55% to 27% Haz [Read more]